
Washington (dbTechno) - The U.S. Food and Drug Administration (FDA) is very concerned about the risks associated with certain asthma drugs, as they have been found to increase the risks of asthma-related deaths and asthma attacks for those who take them.
The drug-safety office of the FDA has already come out and stated that they approve the idea of taking away these class of drugs.
The drugs in question are known as long-acting beta agonist drugs or LABA drugs.
They want to remove them from being given to children who are under the age of 18 due to the increased risks associated with them.
The popular asthma drugs this will impact includes Advair and Serevent from GlaxoSmithKline, Symbicort from AstraZeneca, and Foradil from Novartis.
The same drug-safety office of the FDA wants Serevent and Foradil removed from being given to all people, even adults.
The FDA is going to receive further advice from a panel this week as they are set to meet on Wednesday and Thursday.